Procter & Gamble in-licensed a drug for treating gastrointestinal disorders, the first since its license-and-acquisitions business model took effect earlier this year.
Under the deal, P&G will make an upfront payment of $25 million to the compound’s developer, ARYx Therapeutics.
Payments could reach $435 million over the life of the project, including $250 million before the drug—dubbed ATI-7505—is sold.
The drug is in phase II clinical trials.
P&G once sold another heartburn drug, blockbuster Propulsid (cisapride), but withdrew it in 2000 due to concerns over possible heart problems.
ATI-7505, the firms say, was designed to retain Propulsid’s mechanism of action but without side effects.
The licensing deal with ARYx is the first since P&G announced in February it had decided to acquire new prescription drugs rather than invent them internally.
P&G is honing in on three areas: musculoskeletal, women’s health and gastrointestinal. Drugs it sells in those areas are Actonel for osteoporosis, Enablex for postmenopausal conditions and Asacol for ulcerative colitis.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.